Novo Nordisk's November Gauntlet: A Pediatric Insulin Approval, Exploratory CagriSema Findings and Lilly's Retatrutide Challenge All Converge on 4 November
Published on 10/29/2026 at 13:51 | Editorial boerse-global.de
Novo Nordisk has given investors plenty to read in the run-up to its third-quarter report — and almost none of it settles the question that matters most. A fresh FDA label, a batch of exploratory weight-loss analyses and a rival's head-to-head data have arrived in quick succession, yet the company's own revenue trajectory remains the yardstick against which all of it will eventually be measured.
The regulatory milestone came on 23 October, when the US Food and Drug Administration cleared Awiqli as a once-weekly basal insulin for children aged ten and older with type-2 diabetes, aimed at improving blood-sugar control. That is a categorically different event from the abstracts Novo Nordisk intends to present at scientific meetings. One is a regulatory decision; the others are analyses awaiting scrutiny.
A liver meeting, then a weight congress
Denver hosts The Liver Meeting from 5 to 9 November, where the Danish drugmaker is slated to present real-world semaglutide analyses alongside post-hoc evaluations of the ESSENCE study. Nine days later, Washington's ObesityWeek (14–17 November) will feature 26 scientific contributions spanning everyday experience with Wegovy tablets, injection data and work on CagriSema, which has yet to win approval.
Those ObesityWeek abstracts drill into practical questions: how patients fare outside controlled trials, how weight trajectories evolve, what patients prefer, and how treatment affects the mental preoccupation with food known as "food noise." The SWEEP study, for instance, examines Wegovy tablet use within a digital support programme. Also on the agenda are CagriSema analyses including data from REDEFINE 9, plus STEP-Young results on investigational once-weekly semaglutide in children aged six to under twelve with obesity.
None of this constitutes proof of efficacy. The announcement is a calendar marker — it names the areas under investigation without disclosing what the analyses found.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
What the CagriSema numbers actually say
Some CagriSema data has already surfaced. On 20 October the company reported post-hoc analyses from REDEFINE 1 in women. Across the overall analysis, average weight loss at 68 weeks reached 25.0%, against 3.0% on placebo. Novo Nordisk labelled the findings explicitly as exploratory, and CagriSema remains an investigational compound. Those results are neither an approval decision nor a secured commercial victory.
Investors would do well to keep three tiers separate: confirmed regulatory progress such as Awiqli, marketed products such as Wegovy, and unapproved candidates such as CagriSema. Each carries a different evidentiary standard.
Lilly turns up the heat
Competitive pressure intensified with a direct comparison study from Eli Lilly reported yesterday. According to media accounts, retatrutide produced deeper A1C reductions and more than double the average weight loss of Ozempic at the 2 mg dose in adults with type-2 diabetes. Separately, Reuters reported that Lilly lifted quarterly revenue 39% to USD 24.4 billion and raised its full-year sales guidance.
Strong results for a rival molecule in a different patient group do not automatically answer the same clinical question for Novo Nordisk. Still, they sharpen the scrutiny on how convincingly the company can explain its own trajectory.
The 4 November print comes first
Before any of the congress data lands, Novo Nordisk will publish nine-month results for 2026 on 4 November, before the Copenhagen market opens. The guidance raised in August still points to lower revenue than the prior year. That makes the top-line outlook the first hurdle — not the volume of abstracts on the way.
The sequence matters. A convincing business update would give the later scientific presentations something to reinforce; a weakening outlook would force positive research findings to fight against that drag. Either way, the two must be assessed on separate ledgers. Real-world Wegovy experience may sharpen the picture of how tablets and injections serve different patient preferences, but it answers a different question than a revenue forecast does.
The constructive case rests on additional treatment data supporting the longer-term picture while guidance signals no further deterioration. The bearish case is a combination of continued revenue weakness and congress abstracts that add little genuine insight. In that scenario, scientific activity might illustrate long-range possibilities without easing near-term financial concerns.
What counts is not how many presentations Novo Nordisk brings to Denver and Washington, but what they say — and whether the 4 November numbers leave room for that message to register.
Ad
Novo Nordisk Stock: New Analysis - 29 October
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
